Weakly Supervised Deep Learning Predicts Immunotherapy Response in Solid Tumors Based on PD-L1 Expression.

Journal: Cancer research communications
Published Date:

Abstract

UNLABELLED: Programmed death-ligand 1 (PD-L1) IHC is the most commonly used biomarker for immunotherapy response. However, quantification of PD-L1 status in pathology slides is challenging. Neither manual quantification nor a computer-based mimicking of manual readouts is perfectly reproducible, and the predictive performance of both approaches regarding immunotherapy response is limited. In this study, we developed a deep learning (DL) method to predict PD-L1 status directly from raw IHC image data, without explicit intermediary steps such as cell detection or pigment quantification. We trained the weakly supervised model on PD-L1-stained slides from the non-small cell lung cancer (NSCLC)-Memorial Sloan Kettering (MSK) cohort (N = 233) and validated it on the pan-cancer-Vall d'Hebron Institute of Oncology (VHIO) cohort (N = 108). We also investigated the performance of the model to predict response to immune checkpoint inhibitors (ICI) in terms of progression-free survival. In the pan-cancer-VHIO cohort, the performance was compared with tumor proportion score (TPS) and combined positive score (CPS). The DL model showed good performance in predicting PD-L1 expression (TPS ≥ 1%) in both NSCLC-MSK and pan-cancer-VHIO cohort (AUC 0.88 ± 0.06 and 0.80 ± 0.03, respectively). The predicted PD-L1 status showed an improved association with response to ICIs [HR: 1.5 (95% confidence interval: 1-2.3), P = 0.049] compared with TPS [HR: 1.4 (0.96-2.2), P = 0.082] and CPS [HR: 1.2 (0.79-1.9), P = 0.386]. Notably, our explainability analysis showed that the model does not just look at the amount of brown pigment in the IHC slides, but also considers morphologic factors such as lymphocyte conglomerates. Overall, end-to-end weakly supervised DL shows potential for improving patient stratification for cancer immunotherapy by analyzing PD-L1 IHC, holistically integrating morphology and PD-L1 staining intensity.

Authors

  • Marta Ligero
  • Garazi Serna
    Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Omar S M El Nahhas
    Else Kroener Fresenius Center for Digital Health, Technical University Dresden, Dresden, Germany.
  • Irene Sansano
    Pathology Department, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.
  • Siarhei Mauchanski
    N.N. Alexandrov National Cancer Centre of Belarus, 223040 Minsk, Belarus.
  • Cristina Viaplana
    Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Julien Calderaro
    Department of Pathology, Henri Mondor University Hospital, Créteil, France.
  • Rodrigo A Toledo
    Biomakers and Clonal Dynamics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Rodrigo Dienstmann
    Oncology Data Science Group, Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Rami S Vanguri
    Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
  • Jennifer L Sauter
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Francisco Sanchez-Vega
    Marie-Josée & Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
  • Sohrab P Shah
    From the Departments of Radiology (N.C.S., V.Y., Y.R.C., D.C.G., J.T., V.H., S.S.H., S.K., J.L., K.J., A.I.H., R.J.Y.), Radiation Oncology (J.T.Y.), Neurosurgery (N.M.), Neurology (J.S.), and Epidemiology and Biostatistics, Division of Computational Oncology, (K.P., J.G., S.P.S.), Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; Weill Cornell Medical College, New York, NY (J.K.).
  • Santiago Ramón Y Cajal
    Pathology Department, Vall d'Hebron University Hospital (VHUH), Barcelona, Spain.
  • Elena Garralda
    Department of Medical Oncology, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain.
  • Paolo Nuciforo
    Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Raquel Perez-Lopez
    Radiomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Jakob Nikolas Kather
    Department of Medicine III, University Hospital RWTH Aachen, Aachen, Germany.